<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1.0"><title>Summarize safety data — asr_safety_summary • SwissASR</title><!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.7.1/jquery.min.js" integrity="sha512-v2CJ7UaYy4JwqLDIrZUI/4hqeoQieOmAZNXBeQyjo21dadnwR+8ZaIJVT8EE2iyI61OV8e6M8PP2/4hpQINQ/g==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><!-- Bootstrap --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/css/bootstrap.min.css" integrity="sha256-bZLfwXAP04zRMK2BjiO8iu9pf4FbLqX6zitd+tIvLhE=" crossorigin="anonymous"><script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script><!-- bootstrap-toc --><link rel="stylesheet" href="../bootstrap-toc.css"><script src="../bootstrap-toc.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet"><script src="../pkgdown.js"></script><meta property="og:title" content="Summarize safety data — asr_safety_summary"><meta property="og:description" content="This function creates the text and summary table for the report."><meta property="og:image" content="/logo.png"><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--></head><body data-spy="scroll" data-target="#toc">


    <div class="container template-reference-topic">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">SwissASR</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="">0.5.2</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav"><li>
  <a href="../reference/index.html">Reference</a>
</li>
<li>
  <a href="../news/index.html">Changelog</a>
</li>
      </ul><ul class="nav navbar-nav navbar-right"></ul></div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->



      </header><div class="row">
  <div class="col-md-9 contents">
    <div class="page-header">
    <h1>Summarize safety data</h1>

    <div class="hidden name"><code>asr_safety_summary.Rd</code></div>
    </div>

    <div class="ref-description">
    <p>This function creates the text and summary table for the report.</p>
    </div>

    <div id="ref-usage">
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">asr_safety_summary</span><span class="op">(</span><span class="va">data</span>, <span class="va">period_data</span>, <span class="va">trial_type</span>, <span class="va">n_pat_e</span>, <span class="va">n_per_arm</span><span class="op">)</span></span></code></pre></div>
    </div>

    <div id="arguments">
    <h2>Arguments</h2>


<dl><dt id="arg-data">data<a class="anchor" aria-label="anchor" href="#arg-data"></a></dt>
<dd><p>SAE data</p></dd>


<dt id="arg-period-data">period_data<a class="anchor" aria-label="anchor" href="#arg-period-data"></a></dt>
<dd><p>SAE data restricted to a specific period</p></dd>


<dt id="arg-trial-type">trial_type<a class="anchor" aria-label="anchor" href="#arg-trial-type"></a></dt>
<dd><p>trial type (<code>imp</code>, <code>medical device</code> or <code>other</code>)</p></dd>


<dt id="arg-n-pat-e">n_pat_e<a class="anchor" aria-label="anchor" href="#arg-n-pat-e"></a></dt>
<dd><p>Number of enrolled participants</p></dd>


<dt id="arg-n-per-arm">n_per_arm<a class="anchor" aria-label="anchor" href="#arg-n-per-arm"></a></dt>
<dd><p>Number of participants enrolled per arm</p></dd>

</dl></div>
    <div id="value">
    <h2>Value</h2>

<dl><dt>txt</dt>
<dd><p>The sentences required for the report</p></dd>

<dt>tab</dt>
<dd><p>The summary table required for the report</p></dd>

<dt>tab_map</dt>
<dd><p>Mapping between the variable name in <code>tab</code> and a nicer label</p></dd>


</dl></div>

    <div id="ref-examples">
    <h2>Examples</h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="fu"><a href="https://rdrr.io/r/utils/data.html" class="external-link">data</a></span><span class="op">(</span><span class="va">asr_sae</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="co"># IMP</span></span></span>
<span class="r-in"><span><span class="va">prepped</span> <span class="op">&lt;-</span> <span class="fu"><a href="asr_dataprep.html">asr_dataprep</a></span><span class="op">(</span><span class="va">asr_sae</span>,</span></span>
<span class="r-in"><span>                        period_from <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/as.Date.html" class="external-link">as.Date</a></span><span class="op">(</span><span class="st">"2020-10-10"</span><span class="op">)</span>,</span></span>
<span class="r-in"><span>                        period_to <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/as.Date.html" class="external-link">as.Date</a></span><span class="op">(</span><span class="st">"2021-10-10"</span><span class="op">)</span></span></span>
<span class="r-in"><span>                        <span class="op">)</span></span></span>
<span class="r-in"><span><span class="fu">asr_safety_summary</span><span class="op">(</span>data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">data</span>, period_data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">period_data</span>,</span></span>
<span class="r-in"><span>                   <span class="st">"imp"</span>, <span class="fl">60</span>, n_per_arm <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span>grp1 <span class="op">=</span> <span class="fl">150</span>, grp2 <span class="op">=</span> <span class="fl">150</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "During the reporting period, 20 of 60 participants (33.3 %) reported a total of 20 serious adverse events (SAEs)."                                           </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "5 of 20 SAEs (25.0 %) were classified 'related' to the IMP."                                                                                                 </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [3] "Most frequent related SAEs (i.e., SADR.) documented were poor sleep (2), spontaneous unconsciousness (2), headache (1)."                                     </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [4] "6 Suspected Unexpected Serious Adverse Reactions (SUSARs) occurred during the reporting period, which have been notified to the Swiss competent authorities."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt_all</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "Since the beginning of the study, 20 of 60 participants (33.3 %) reported a total of 20 serious adverse events (SAEs)."                                      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "5 of 20 SAEs (25.0 %) were classified 'related' to the IMP."                                                                                                 </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [3] "Most frequent related SAEs (i.e., SADR.) documented were poor sleep (2), spontaneous unconsciousness (2), headache (1)."                                     </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [4] "6 Suspected Unexpected Serious Adverse Reactions (SUSARs) occurred during the reporting period, which have been notified to the Swiss competent authorities."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #949494;"># A tibble: 2 × 5</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   desc                                                   fatal sae   sadr  susar</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>                                                  <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span> <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span> <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span> <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">1</span> Number of cases (during reporting period)              N = … N = … N = … N = …</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">2</span> Number of cases (cumulative) since the start of the c… N = … N = … N = … N = …</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab_map</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   col_key</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    desc</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2   fatal</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3     sae</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4    sadr</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5   susar</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                     name</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1                                                                    IMP</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2                       Serious Adverse Events, SAEs, with fatal outcome</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3                           Other Serious Adverse Events, non-fatal SAEs</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4                  Serious Adverse Drug Reactions, SADRs (only for IMPs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5 Suspected Unexpected Serious Adverse Reactions, SUSARs (only for IMPs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="co"># medical devices</span></span></span>
<span class="r-in"><span><span class="va">prepped</span> <span class="op">&lt;-</span> <span class="fu"><a href="asr_dataprep.html">asr_dataprep</a></span><span class="op">(</span><span class="va">asr_sae</span>, period_from <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/as.Date.html" class="external-link">as.Date</a></span><span class="op">(</span><span class="st">"2020-10-10"</span><span class="op">)</span>,</span></span>
<span class="r-in"><span>                        period_to <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/as.Date.html" class="external-link">as.Date</a></span><span class="op">(</span><span class="st">"2021-10-10"</span><span class="op">)</span>, trial_type <span class="op">=</span> <span class="st">"m"</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="fu">asr_safety_summary</span><span class="op">(</span>data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">data</span>,</span></span>
<span class="r-in"><span>                           period_data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">period_data</span>, <span class="st">"m"</span>, <span class="fl">60</span>,</span></span>
<span class="r-in"><span>                            n_per_arm <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span>grp1 <span class="op">=</span> <span class="cn">NA</span>, grp2 <span class="op">=</span> <span class="cn">NA</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [1] "During the reporting period, a total of 20 serious adverse events (SAEs) have been reported."                                                                                                                                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [2] "5 out of 20 SAEs (25.0 %) were classified ''related'' to the MD or to an intervention (procedure) undertaken in the clinical trial."                                                                                                            </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [3] "In 11 of 20 SAEs (55.0 %) it cannot be excluded that the events are attributable to the medical device under investigation."                                                                                                                    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [4] "In 7 of 20 SAEs (35.0 %) it cannot be excluded that the events are attributable to an intervention undertaken in the clinical trial."                                                                                                           </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [5] "The most frequent SAEs documented were spontaneous unconsciousness (7), headache (5), poor sleep (4)."                                                                                                                                          </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [6] "Occurrence of SAE in the trial arm versus control arm (if applicable)."                                                                                                                                                                         </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [7] "With respect to the expectedness of the event, 7 (35.0 %) of the SADEs were expected/anticipated and 13 (65.0 %) were classified as unexpected/unanticipated."                                                                                  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [8] "11 device deficiencies were observed (includes malfunctions, use errors, inadequacies in the information supplied by the manufacturer including labelling)."                                                                                    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [9] "11 out of 11 device deficiencies (100.0 %) could have led to serious adverse events if suitable action had not been taken, intervention had not been made, or circumstances had been less fortunate (device deficiencies with a SAE potential)."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [10] "12 health hazards that required safety-related measures occurred."                                                                                                                                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [11] "Safety and protective measures taken by the investigator/sponsor (including those requested by the ethics committee and Swissmedic and authorities abroad) taken in Switzerland and abroad: [free text]"                                        </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt_all</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [1] "During the reporting period, a total of 20 serious adverse events (SAEs) have been reported."                                                                                                                                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [2] "5 out of 20 SAEs (25.0 %) were classified ''related'' to the MD or to an intervention (procedure) undertaken in the clinical trial."                                                                                                            </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [3] "In 11 of 20 SAEs (55.0 %) it cannot be excluded that the events are attributable to the medical device under investigation."                                                                                                                    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [4] "In 7 of 20 SAEs (35.0 %) it cannot be excluded that the events are attributable to an intervention undertaken in the clinical trial."                                                                                                           </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [5] "The most frequent SAEs documented were spontaneous unconsciousness (7), headache (5), poor sleep (4)."                                                                                                                                          </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [6] "Occurrence of SAE in the trial arm versus control arm (if applicable)."                                                                                                                                                                         </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [7] "With respect to the expectedness of the event, 7 (35.0 %) of the SADEs were expected/anticipated and 13 (65.0 %) were classified as unexpected/unanticipated."                                                                                  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [8] "11 device deficiencies were observed (includes malfunctions, use errors, inadequacies in the information supplied by the manufacturer including labelling)."                                                                                    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [9] "11 out of 11 device deficiencies (100.0 %) could have led to serious adverse events if suitable action had not been taken, intervention had not been made, or circumstances had been less fortunate (device deficiencies with a SAE potential)."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [10] "12 health hazards that required safety-related measures occurred."                                                                                                                                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [11] "Safety and protective measures taken by the investigator/sponsor (including those requested by the ethics committee and Swissmedic and authorities abroad) taken in Switzerland and abroad: [free text]"                                        </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #949494;"># A tibble: 2 × 4</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   desc                                                       sade  attr measures</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>                                                     <span style="color: #949494; font-style: italic;">&lt;int&gt;</span> <span style="color: #949494; font-style: italic;">&lt;int&gt;</span>    <span style="color: #949494; font-style: italic;">&lt;int&gt;</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">1</span> Number of cases (during reporting period)                     0    11       12</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">2</span> Number of cases (cumulative) since the start of the clin…     0    11       12</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab_map</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   col_key</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    desc</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2    sade</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3   fatal</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4     sae</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                       name</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1                                                            MD/IVD Device</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2                                      Serious Adverse Device Effects SADE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3 Device Deficiencies that could have led to an SAE (serious deficiencies)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4          Safety and protective measures taken in Switzerland and abroad.</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="co"># other trial</span></span></span>
<span class="r-in"><span><span class="fu">asr_safety_summary</span><span class="op">(</span>data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">data</span>, period_data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">period_data</span>, <span class="st">"o"</span>, <span class="fl">60</span>,</span></span>
<span class="r-in"><span> n_per_arm <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span>grp1 <span class="op">=</span> <span class="fl">150</span>, grp2 <span class="op">=</span> <span class="fl">150</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "During the reporting period, 20 of 60 participants (33.3 %) reported a total of 20 serious adverse events (SAEs) with possible relationship to the study intervention)."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "The most frequent documented SAEs with possible relationship to the intervention were poor sleep (2), spontaneous unconsciousness (2), headache (1)."                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt_all</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "Since the beginning of the study, 20 of 60 participants (33.3 %) reported a total of 20 serious adverse events (SAEs) with possible relationship to the study intervention)."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "The most frequent documented SAEs with possible relationship to the intervention were poor sleep (2), spontaneous unconsciousness (2), headache (1)."                        </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #949494;"># A tibble: 2 × 3</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   desc                                                              fatal nfatal</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>                                                             <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span> <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">1</span> Number of cases (during reporting period)                         N = … N = 5…</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">2</span> Number of cases (cumulative) since the start of the clinical tri… N = … N = 4…</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab_map</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   col_key</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    desc</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2   fatal</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3     sae</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                               name</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1                                                             Other clinical trial</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2 SAEs with fatal outcome where a causality to the intervention cannot be excluded</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3              Other SAEs where a causality to the intervention cannot be excluded</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="co"># tpr trial</span></span></span>
<span class="r-in"><span><span class="fu">asr_safety_summary</span><span class="op">(</span>data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">data</span>, period_data <span class="op">=</span> <span class="va">prepped</span><span class="op">$</span><span class="va">period_data</span>, <span class="st">"t"</span>, <span class="fl">60</span>,</span></span>
<span class="r-in"><span> n_per_arm <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span>grp1 <span class="op">=</span> <span class="fl">150</span>, grp2 <span class="op">=</span> <span class="fl">150</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "During the reporting period, a total of 20 Serious Adverse Events (SAEs) occurred."                                                                                                                      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "5 of 20 SAEs (25.0 %) were classified as Serious Adverse Drug Reaction (SADR) i.e., serious adverse events with possible relationship to the TrP/GT/GMO administered."                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [3] "The most frequent SADR documented were spontaneous unconsciousness (7), headache (5), poor sleep (4)."                                                                                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [4] "In 1 out of 5 SADRs (20.0 %) it cannot be excluded that the events are attributable to the TrP/GT/GMO itself."                                                                                           </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [5] "In 4 out of 5 SADRs (80.0 %) it cannot be excluded that the events are attributable to other factors like quality defects, contaminations, administration and preparation procedures of TrP/GT/GMO, etc."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [6] "6 Suspected Unexpected Serious Adverse Reactions (SUSARs) occurred during the reporting period."                                                                                                         </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [7] "Other new relevant safety aspects (including details regarding exposure): "                                                                                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $txt_all</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [1] "Since the beginning of the study, a total of 20 Serious Adverse Events (SAEs) occurred."                                                                                                                 </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [2] "5 of 20 SAEs (25.0 %) were classified as Serious Adverse Drug Reaction (SADR) i.e., serious adverse events with possible relationship to the TrP/GT/GMO administered."                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [3] "The most frequent SADR documented were spontaneous unconsciousness (7), headache (5), poor sleep (4)."                                                                                                   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [4] "In 1 out of 5 SADRs (20.0 %) it cannot be excluded that the events are attributable to the TrP/GT/GMO itself."                                                                                           </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [5] "In 4 out of 5 SADRs (80.0 %) it cannot be excluded that the events are attributable to other factors like quality defects, contaminations, administration and preparation procedures of TrP/GT/GMO, etc."</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [6] "6 Suspected Unexpected Serious Adverse Reactions (SUSARs) occurred during the reporting period."                                                                                                         </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> [7] "Other new relevant safety aspects (including details regarding exposure): "                                                                                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #949494;"># A tibble: 2 × 6</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   desc                                            fatal nfatal nsadr sadr  susar</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>                                           <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span> <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span>  <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span> <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span> <span style="color: #949494; font-style: italic;">&lt;chr&gt;</span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">1</span> Number of cases (during reporting period)       N = … N = 5… N = … N = … N = …</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> <span style="color: #BCBCBC;">2</span> Number of cases (cumulative) since the start o… N = … N = 1… N = … N = … N = …</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> $tab_map</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   col_key                                                   name</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1    desc                                                       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2   fatal                                SAEs with fatal outcome</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3  nfatal          Other Serious Adverse Events (non-fatal SAEs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4   nsadr             Non-Serious Adverse Drug Reactions, NSADRs</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5    sadr                  Serious Adverse Drug Reactions, SADRs</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 6   susar Suspected Unexpected Serious Adverse Reactions, SUSARs</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> </span>
</code></pre></div>
    </div>
  </div>
  <div class="col-md-3 hidden-xs hidden-sm" id="pkgdown-sidebar">
    <nav id="toc" data-toggle="toc" class="sticky-top"><h2 data-toc-skip>Contents</h2>
    </nav></div>
</div>


      <footer><div class="copyright">
  <p></p><p>Developed by Alan G. Haynes, Mattia Branca.</p>
</div>

<div class="pkgdown">
  <p></p><p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.0.</p>
</div>

      </footer></div>






  </body></html>

